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Introduction:

Case Study:

PFO device insertion:

A patent foramen ovale (PFO) is a hole in the
atrial septum used for fetal circulation. After
birth, this hole usually closes to increase blood
pressures within the heart. In 25% of the world’s
population, the septum never fully closes. A
PFO causes a right to left shunt where emboli
can travel from the venous side to the arterial
side causing a stroke. Cryptogenic strokes are
unexplained in origin but may be caused by a
PFO. (Kern, 2016)

The patient is a 62-year-old male with a
history of cerebrovascular disease and
hypertension. He had a recent
Cerebrovascular Accident (CVA) and was
found to have a PFO.

The patient was given mild sedation and a
local anesthesia to both groins. Vascular
access was obtained in both femoral veins. A
Swan-Ganz Catheter was introduced to
evaluate right heart pressures and blood
saturations. A 5 Fr multipurpose catheter was
used to cross the PFO and was positioned in
the pulmonary vein. The catheter was replaced
with a 9 Fr sheath and advanced across the
defect with an Amplatzer wire. The PFO was
evaluated with a sizing balloon to determine
what size device would be used. (Kern, 2016)

Treatment Options:
Surgical Closure requires a thoracotomy and
cardiopulmonary bypass. This treatment option
is rarely chosen, unless the patient is already
receiving another open cardiovascular
procedure. 73% of the surgical patient’s still
have recurrent cryptogenic strokes due to
incomplete PFO closure. (Saver, 2018)

Pre-Op Imaging Studies:
CT with intravenous contrast:
• Used to determine size and shape of
defect. (Pathan, 2018)
No malignancy identified in the chest,
abdomen or pelvis. No concerning findings.

PFO Device deployed:

The Image above depicts the deployed closure device

Transesophageal Echocardiogram (TEE):

Post procedure patient care:

• Used to evaluate the atrial septum before,
during and after the procedure. (Pathan, 2018)

The long 9 Fr sheath was replaced with a short
9 Fr sheath and secured with a figure of 8stitch to be removed later
•

PFO DEVICE:

Limited TEE study before discharge
•

The image above demonstrates the sizing balloon
measuring the size and shape of the defect

The image above demonstrates a PFO closure device
https://www.openpr.com/news/1031493/global-pfo-closure-device-market-poised-to-take-off-by-2023.html

The Amplatzer device is a double-disk nitinol
mesh and polyester fiber device that sits on
either side of the septal defect. (Kern, 2016)

The Image above demonstrates a presence of a small
right to left shunt through the PFO while at rest by
saline contrast injection.

This design has caused significantly less
complications than other devices.(Saver, 2018)

Drug Therapy Compared to Device Closure
Six randomized clinical trials were conducted
comparing medical drug therapies to a PFO
closure device. Each trial looked at different
combinations of treatment options with different
drug therapies and devices. (Saver, 2018)
The RESPECT Trial conducted in 2013 was the
first trial that showed a significant impact in
reducing recurrent cryptogenic strokes by 45
percent, making the closure device the standard
of treatment. (Saver, 2017)
Trials conducted from 2017 to 2018 such as the
DEFENSE-PRO Trial further developed PFO
device methods over medical drug therapy
alone. It was found to be more significant for
patient’s who have an aneurysmal atrial septum
and a PFO. (Saver, 2018)

After sizing the defect, a 25 mm Amplatzer PFO
occluder device was prepared and passed
through the delivery sheath. The left atrial disk
was deployed, and the right atrial disk was
deployed. Fluoroscopy and an intracardiac
echo were used to determine correct
placement. The Minnesota Wiggle Test was
also performed to determine accurate
placement and sizing.
The Minnesota Wiggle Test is performed to
ensure the device is stable enough to be
released. The physician gently pushes forward
and pulls backwards on the Amplatzer wire.
Successful placement is determined by the
lack of movement of the device in either
direction. (Kern, 2016)

The image above demonstrates the atrial septal
defect. This image shows a mildly aneurysmal
atrial septum and no mass or thrombus present
on atrial appendage.

The patient was considered for a PFO
closure device due to his recurrent
cryptogenic strokes. All other test performed
were considered normal.

The device is released off the delivery wire
using a pin vise, rotating the wire in a
counterclockwise motion. (Kern, 2016)
The device was detached and a bubble study
with Valsalva maneuver was performed to
assess for shunting. (Kern, 2016)

no atrial shunt demonstrated

•

Infective endocarditis prophylaxis for at
least 6- 12 months

•

Recommended 81 mg of Aspirin per day
indefinitely.

•

Recommended Clopidogrel 75 mg at least 3
months.

•

Follow-up TEE appointment at 3 months. If
closure is complete, Plavix may be stopped.

Conclusion:
There are several treatment options used to
treat cryptogenic strokes in patients who have
a patent foramen ovale. Open surgical
procedures prove to be unnecessary due to
the harm it can cause to patient. Medical drug
therapy alone still puts the patients at risk to
have recurrent ischemic strokes because the
physical problem is not being treated. PFO
closure devices when combined with medical
drug therapies have been found to
significantly impact the rate of recurrent
cryptogenic strokes in PFO patients.
Because of the success in the RESPECT Trial,
the FDA approved the PFO occluder as a
viable treatment option on October 28, 2016.
(Mojadidi, 2018)

This option is continuously being studied in
attempt to further advance it making it more
effective for future patients. This life saving
treatment significantly improves the quality of
life for recurrent cryptogenic stroke patients.
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